Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Provided By GlobeNewswire
Last update: Feb 11, 2025
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25
If approved, FILSPARI could be the first and only approved medicine indicated for FSGS, a rare kidney disorder and leading cause of kidney failure
Read more at globenewswire.com20.76
-0.05 (-0.24%)
Find more stocks in the Stock Screener
TVTX Latest News and Analysis
2 hours ago - ChartmillIs TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX).
